TickerGuard
Buy Day today: Poor (58) Mixed market breadth · today: CPI (July)
AVTR

Avantor Inc

Healthcare · Medical Instruments & Supplies

13.80$ +0.3% vs. previous close Closing price · As of: Aug 11, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Avantor Inc (AVTR). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — AVTR
Segment 2020 2021 2022 2023 2024 2025
Laboratory Solutions $5.00B 66.6% $4.74B 68.0% · -5.3% $4.61B 68.0% · -2.7% $4.40B 67.1% · -4.6%
Bioscience Production $2.51B 33.4% $2.23B 32.0% · -11.2% $2.17B 32.0% · -2.5% $2.15B 32.9% · -1.0%
Americas $3.73B 58.4% $4.24B 57.4% · +13.6%
Europe $2.29B 35.8% $2.68B 36.2% · +17.1%
AMEA $375.4M 5.9% $471.4M 6.4% · +25.6%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — AVTR
Segment 2020 2021 2022 2023 2024 2025
Proprietary materials & consumables $2.04B 32.0% $2.55B 34.5% · +24.7% $4.02B 53.6% · +57.9% $3.72B 53.4% · -7.6% $3.62B 53.3% · -2.8% $3.45B 52.6% · -4.6%
Third party materials & consumables $2.67B 41.8% $2.91B 39.3% · +8.8% $3.49B 46.4% · +20.0% $3.25B 46.6% · -6.9% $3.17B 46.7% · -2.4% $3.10B 47.4% · -2.1%
Services & specialty procurement $817.5M 12.8% $922.6M 12.5% · +12.9%
Equipment & instrumentation $860.7M 13.5% $1.01B 13.7% · +17.2%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?